Journal for ImmunoTherapy of Cancer: 13 (4)

Basic and translational cancer immunology

Original research: Selective BCL-2 inhibitor triggers STING-dependent antitumor immunity via inducing mtDNA release (29 April, 2025)
Wenxin Zhang, Xiaohui Pan, Longsheng Wang, Wen Li, Xiaoyang Dai, Mingming Zheng, Hongjie Guo, Xi Chen, Yanjun Xu, Honghai Wu, Qiaojun He, Bo Yang, Ling Ding
Original research: Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer (24 April, 2025)
Yilin Chen, Lu Yang, Yuhong Huang, Teng Zhu, Liulu Zhang, Minyi Cheng, Cangui Wu, Peiyong Li, Minting Liang, Xiaoqi Zhang, Hao Peng, Kun Wang
Original research: Gut microbiota derived indole-3-acetic acid ameliorates precancerous inflammatory intestinal milieu to inhibit tumorigenesis through IL-35 (23 April, 2025)
Juanjuan Wang, Yang Hao, Yazheng Yang, Yuan Zhang, Chen Xu, Rongcun Yang
Original research: Reversible downregulation of HLA class I in adenoid cystic carcinoma (20 April, 2025)
Annie Li, Bianca L Gonda, Elizabeth M Codd, Adam von Paternos, Dawn R Mitchell, Markus D Herrmann, Prinjali Kalyan, Samantha E Flynn, Thuc Q Dzu, Chengzhuo Gao, Edwin Zhang, Julia J Mendel, Julia C Thierauf, Peter M Sadow, Thomas Denize, Diane Yang, Florian J Fintelmann, Jo Anne Fordham, Ross D Merkin, Atul K Bhan, Yu-Chung Huang, Jeffrey Raizer, William C Faquin, Daniel L Faden, Xin Gao, Jong Chul Park, Lori J Wirth, Stefan T Kaluziak, A. John Iafrate
Original research: Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v (17 April, 2025)
Hana Matuskova, Pavel Marasek, Vladyslav Mazhara, Ekaterina Simonova, Lucie Kosinova, Petr Danek, Klara Danova, Katerina Sajnerova, Iva Malatova, Klara Hrabankova, Denise Greco, Ondrej Martinec, Matej Fabisik, Nada Podzimkova, Kamila Hladikova, Katerina Behalova, Zuzana Antosova, Milada Sirova, Romana Mikyskova, Milan Reinis, Marek Kovar, David Béchard, Ulrich Moebius, Lenka Palova Jelinkova, Radek Spisek, Martin Steegmaier, Irena Adkins
Original research: Shp-1 regulates the activity of low-affinity T cells specific to endogenous self-antigen during melanoma tumor growth and drives resistance to immune checkpoint inhibition (17 April, 2025)
Joseph G Matous, Jeremy P Snook, Nico A Contreras, Andrew G Ramstead, Krystal R Charley, Elizabeth M Kolawole, Jacob N Kisiolek, Kaitlyn A Flint, Ashleigh J Soedel, Breyana Robinson, Anaiya B Mendoza, Yohichi Kumaki, Brian D Evavold, Matthew A Williams
Original research: METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5/CCL5 regulation (15 April, 2025)
Yonghua Tong, Zhiqiang Chen, Jian Wu, Qiu Huang, Yu He, Haojie Shang, Ding Xia, Ejun Peng, Zhihua Wang, Xiaoyu Liang, Kun Tang
Original research: PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development (15 April, 2025)
Steffen Lemke, Marissa L Dubbelaar, Patrick Zimmermann, Jens Bauer, Annika Nelde, Naomi Hoenisch Gravel, Jonas Scheid, Marcel Wacker, Susanne Jung, Anna Dengler, Yacine Maringer, Hans-Georg Rammensee, Cecile Gouttefangeas, Sven Fillinger, Tatjana Bilich, Jonas S Heitmann, Sven Nahnsen, Juliane S Walz
Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects (10 April, 2025)
Michela Capello, Angelica Sette, Theo Plantinga, Craig J Thalhauser, Vanessa M Spires, Kristina B Nürmberger, Jordan M Blum, Brandon W Higgs, Patricia Garrido Castro, Christina Yu, Carol Costa Sa, Sina Fellermeier-Kopf, Saskia M Burm, Kristin Strumane, Aras Toker, Andrea Imle, Bruna de Andrade Pereira, Alexander Muik, Tahamtan Ahmadi, Özlem Türeci, Mark Fereshteh, Ugur Sahin, Maria Jure-Kunkel, Nora Pencheva
Original research: PRMT5 deficiency in myeloid cells reprograms macrophages to enhance antitumor immunity and synergizes with anti-PD-L1 therapy (5 April, 2025)
Shiyu Chen, Zheyi Chen, Bingqian Zhou, Yongyu Chen, Yiren Huang, Jian Cao, Lisong Shen, Yingxia Zheng
Original research:
Targeting PD-1 and CD85j can restore intratumoral CD4⁺ GzmB⁺ T-cell functions to combat MHC-II-expressing tumors
(1 April, 2025)
Boyu Wang, Xu Wang, Tianlai Wang, Kelin Meng, Taiyan Yu, Yu Xi, Shaojie Hu, Hui Xiong, Rirong Qu, Zhiwei Yuan, Xue Wang, Chenxi Zeng, Wenbin Zou, Yitao Tian, Yixin Cai, Shengling Fu, Xiangning Fu, Lequn Li

Basic tumor immunology

Original research:
Memory-promoting function of miR-379-5p attenuates CD8⁺ T cell exhaustion by targeting immune checkpoints
(12 April, 2025)
You-Zhe Lin, Chia-Hsin Liu, Wan-Rong Wu, Ting-Yi Liao, Chuan-Chun Lee, Hong-Wei Li, Feng-Chi Chung, Yi-Chun Shen, Guan-Yu Zhuo, Liang-Chih Liu, Wei-Chung Cheng, Shao-Chun Wang
Original research: Neural crest-associated gene FOXD1 induces an immunosuppressive microenvironment by regulating myeloid-derived suppressor cells in melanoma (9 April, 2025)
Qian Sun, Nina Wang, Juliane Poelchen, Mareike Peter, Daniel Novak, Feyza Gül Özbay Kurt, Rebekka Bitsch, Huizi Wu, Yiman Wang, Sandra Pardo, Rui Han, Shibo Liu, Lidong Gong, Yuxin Zhang, Kilian Wistuba-Hamprecht, Viktor Umansky, Jochen Sven Utikal
Original research: MHC class II-mediated spontaneous rejection of breast carcinomas expressing model neoantigens (5 April, 2025)
James William Jenkins, Alvaro Peña, Sarah A Castro, Michael J Hansen, Virginia P Van Keulen, Sean T Foster, Pablo E Rios-Cruz, Joshua Yakubov, Destin T Hinson, Samuel M Olivier, Kevin D Pavelko, Sara J Felts, Aaron J Johnson, Larry R Pease

Case report

First reported case of a spontaneous and healthy pregnancy in a woman with persistent CAR T-cells 5 years after treatment for diffuse large B-cell lymphoma (1 April, 2025)
Ethan Abraham Canty, Lori Broderick, Daniel Flaherty, Marin Xavier, Sunita D Nasta, Lina Dajani, Andrew A White

Clinical/translational cancer immunotherapy

Original research: LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity (17 April, 2025)
Des C Jones, Lorraine Irving, Rebecca Dudley, Seraina Blümli, Marcin Wolny, Elisavet I Chatzopoulou, Stacy Pryts, Shreya Ahuja, D Gareth Rees, Alan M Sandercock, Saravanan Rajan, Reena Varkey, Michael Kierny, Andrew Kayserian, Kathy Mulgrew, Georgina Bowyer, Saly Songvilay, Kamila Bienkowska, Matthew S Glover, Sonja Hess, Simon J Dovedi, Robert W Wilkinson, Fernanda Arnaldez, Mark Cobbold
Original research: Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphoma (9 April, 2025)
Charlotte Junkuhn, Phillip Schiele, Anna Luzie Walter, Frederik Hamm, Benedikt Obermayer, David Busch, Andrea Stroux, Mareike Frick, Olaf Penack, Frederik Damm, Julia Polansky, Lars Bullinger, Annette Künkele, Marco Frentsch, Il-Kang Na
Original research: Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors (2 April, 2025)
Koichi Jinushi, Takuro Saito, Koji Kurose, Susumu Suzuki, Takashi Kojima, Taishi Takahara, Tomoki Makino, Tetsuya Ogawa, Hiroyoshi Nishikawa, Kazuhiro Kakimi, Shinsuke Iida, Jun Nakajima, Yuichiro Doki, Mikio Oka, Ryuzo Ueda, Hisashi Wada
Original research: Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade (2 April, 2025)
Marcel Arias-Badia, Chien-Chun Steven Pai, Yee May Lwin, PeiXi Chen, Aahir Srinath, Miho Tanaka, Emily Musser, Andrew Goodearl, Jacob V Gorman, Wendy Ritacco, Lawrence Fong

Clinical cancer immunotherapy

Original research: Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study (28 April, 2025)
Kamran A Ahmed, Younchul Kim, Sungjune Kim, Min Hsuan Wang, Michelle DeJesus, John A Arrington, Aixa E Soyano, Avan J Armaghani, Ricardo L B Costa, Loretta S Loftus, Marilin Rosa, Jimmy J Caudell, Roberto Diaz, Arnold B Etame, Nam D Tran, Hatem Soliman, Brian J Czerniecki, Peter A Forsyth, Hsiang-Hsuan Michael Yu, Hyo S Han
Original research: Onset and progression of atherosclerosis in patients with melanoma treated with immune checkpoint inhibitors (24 April, 2025)
Daan C H van Dorst, Tom J J Uyl, Astrid A M Van der Veldt, Timy Andrawes, Arjen Joosse, Esther Oomen-De Hoop, Alexander HJ Danser, Ron H J Mathijssen, Daniel Bos, Jorie Versmissen
Original research: CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy (17 April, 2025)
Regina M Myers, Amanda M DiNofia, Yimei Li, Caroline Diorio, Hongyan Liu, Gerald Wertheim, Joseph A Fraietta, Vanessa Gonzalez, Gabriela Plesa, Donald L Siegel, Emma Iannone, Laura Shinehouse, Jennifer L Brogdon, Clare Taylor, Julie K Jadlowsky, Elizabeth O Hexner, Boris Engels, Diane Baniewicz, Colleen Callahan, Marco Ruella, Richard Aplenc, Allison Barz Leahy, Susan E McClory, Susan R Rheingold, Lisa Wray, Carl H June, Shannon L Maude, Noelle V Frey, Stephan A Grupp
Original research: Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer (12 April, 2025)
Ying Jiang, Zhiwen Qian, Cenzhu Wang, Danping Wu, Lu Liu, Xin Ning, Yilan You, Jie Mei, Xiaoqian Zhao, Yan Zhang
Original research: Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial (8 April, 2025)
Meiting Chen, Riqing Huang, Qixiang Rong, Wei Yang, Xiujiao Shen, Qi Sun, Ditian Shu, Kuikui Jiang, Cong Xue, Jing Peng, Xin An, Haifeng Li, Fei Xu, Yanxia Shi
Original research:
JAK3 ^A573V and JAK3 ^M511I mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway
(8 April, 2025)
Ning Lou, Mengwei Yang, Zucheng Xie, Ruyun Gao, Lei Zhang, Le Tang, Jiarui Yao, Xiaohong Han, Yuankai Shi
Original research: Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer (5 April, 2025)
Sylvia Adams, Sandra Demaria, Darawan Rinchai, Ena Wang, Yelena Novik, Ruth Oratz, Maria Fenton-Kerimian, Pascale G Levine, Xiaochun Li, Francesco Marincola, Ping Jin, David Stroncek, Judith Goldberg, Davide Bedognetti, Silvia Chiara Formenti
Original research: Characteristics of second primary malignancies following bispecific antibodies therapy (5 April, 2025)
Xiaojie Liang, Baiwei Luo, Bingyu Lin, Dan Liu, Jia Guo, Weixiang Lu, Shengyu Tian, Zihong Cai, Xinyu Zhou, Zhihao Jin, Tong Li, Keren Chen, Hongsheng Zhou, Liang Wang

Commentary

Tumor-infiltrating mast cells as potential chemoimmunotherapy enhancer in triple-negative breast cancer (30 April, 2025)
Pinchao Fan, Chengjun Zhu, Xiaoxiang Guan
Gut reactions: harnessing microbial metabolism to fuel next-generation cancer immunotherapy (29 April, 2025)
Andrew A. Almonte, Laurence Zitvogel
Go to the scene: T_H9 cells superior migration ability to the lungs explains their exceptional anticancer efficacy
(28 April, 2025)
Jiazhi Xu, Lionel Apetoh
Utilization of exosome-based therapies to augment anti-PD-1/PD-L1 therapies (24 April, 2025)
John S. Wang, Samer Yassin, Adam Y. Lin
Plasticity of tumor cell immunogenicity: is it druggable? (23 April, 2025)
Glenn Dranoff
Radiomics in head and neck squamous cell carcinoma – a leap towards precision oncology (23 April, 2025)
Pranjal Rai, Abhishek Mahajan
Past failures and new horizons: the nuances of tertiary lymphoid structures in high-grade serous ovarian cancer may contribute to immunotherapy effectiveness (17 April, 2025)
Rufiaat Rashid, Lan Coffman, Tullia C Bruno, Ian MacFawn
Tumor-infiltrating lymphocyte immunotherapy comes of age: a journey of development in the Surgery Branch, NCI (9 April, 2025)
Stephanie L Goff, Steven A Rosenberg
Unlocking the power of the microbiome for successful cancer immunotherapy (2 April, 2025)
Maria A Clavijo-Salomon, Giorgio Trinchieri

Hypothesis

Irreversible electroporation synergizes with oncolytic virus enhances the infiltration of cytotoxic T lymphocytes in the tumor immune microenvironment: a leap from focal therapy to immunotherapy for prostate cancer (15 April, 2025)
Zhi-Yu Xia, Jia-Cheng Xiang, Jin-Zhou Xu, Jian-Xuan Sun, Shaogang Wang, Qi-Dong Xia

Immune cell therapies and immune cell engineering

Original research: CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression (30 April, 2025)
Javier Arroyo-Ródenas, Aida Falgas, Laura Díez-Alonso, Alba Martinez-Moreno, Heleia Roca-Ho, Francisco J. Gil-Etayo, Alba Pérez-Pons, Óscar Aguilar-Sopeña, Miriam Velasco-Sidro, Marina Gómez-Rosel, Beatriz Jiménez-Matías, Guillermo Muñoz-Sánchez, Yedra Pacheco, Clara Bravo-Martín, Ángel Ramírez-Fernández, Anaïs Jiménez-Reinoso, Europa Azucena González-Navarro, Manel Juan, Alberto Orfao, Belén Blanco, Pedro Roda-Navarro, Clara Bueno, Pablo Menéndez, Luis Álvarez-Vallina
Original research: Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy (29 April, 2025)
Arne Van der Vreken, Fabien Thery, Chenggong Tu, Kevin Mwangi, Sofie Meulewaeter, Lien De Beck, Edith Janssens, Kim De Veirman, Karin Vanderkerken, Elke De Bruyne, Lorenzo Franceschini, Francis Impens, Rein Verbeke, Ine Lentacker, Eline Menu, Karine Breckpot
Original research: CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity (23 April, 2025)
Kerry A Whalen, Catherine C Henry, Naveen K Mehta, Kavya Rakhra, Safak Yalcin, Kristan Meetze, Neil W Gibson, Patrick A Baeuerle, Jennifer S Michaelson
Original research: MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence (20 April, 2025)
Margaux Tual, Angélique Bellemare-Pelletier, Susan Moore, Delphine Guipouy, Negar Farzam-Kia, Leila Jafarzadeh, Jordan Quenneville, Benoit Barrette, Marc K Saba-El-Leil, Jean-Sebastien Delisle, Etienne Gagnon
Original research: Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapy (17 April, 2025)
Enoch Tin, Ismat Khatri, Karen Fang, Yoosu Na, Michele Nawata, Juan Arteaga, Mark D Minden, Sergio Rutella, Jongbok Lee, Li Zhang
Original research: T-bet overexpression enhances CAR T cell effector functions and antigen sensitivity (17 April, 2025)
Jennifer M Cimons, Kole R DeGolier, Samuel D Burciaga, Michael C Yarnell, Amanda J Novak, Amalia M Rivera-Reyes, M. Eric Kohler, Terry J Fry
Original research: CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma (15 April, 2025)
Monica M Cho, Longzhen Song, Aicha E Quamine, Fernanda Szewc, Lei Shi, Johnathan D Ebben, David P Turicek, Jillian M Kline, Devin M Burpee, Emily O Lafeber, Madison F Phillips, Amanda S Ceas, Paul D Bates, Matthew H Forsberg, John A Kink, Amy K Erbe, Christian M Capitini
Original research: CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion (8 April, 2025)
Renata Ariza Marques Rossetti, Leticia Tordesillas, Matthew S Beatty, Junior Cianne, Elena Martinez Planes, Dongliang Du, Sebastian Snedal, Chao Wang, Bradford A Perez, Anders Berglund, Yian Ann Chen, Amod Sarnaik, James J Mulé, Benjamin Creelan, Shari Pilon-Thomas, Daniel Abate-Daga
Original research: Flagellin engineering enhances CAR-T cell function by reshaping tumor microenvironment in solid tumors (5 April, 2025)
Xiangyun Niu, Pengchao Zhang, Liujiang Dai, Xixia Peng, Zhongming Liu, Yexiao Tang, Guizhong Zhang, Xiaochun Wan
Original research: Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers (5 April, 2025)
Manpreet Kaur, Katja Rüger, Elaine C Chen, Udaya S Rangaswamy, Laura M Davison, Sebastian Moreno Arteaga, Imani Smith, Ruth Chu, Soumili Chattopadhyay, Mathias Rickert, Shelley Force Aldred, Katherine E Harris, Nathan D Trinklein, Starlynn C Clarke
Original research: IL-12-producing cytokine factories induce precursor exhausted T cells and elimination of primary and metastatic tumors (1 April, 2025)
Amanda Nash, Jonathon DeBonis, Danna Murungi, Bertha Castillo, Boram Kim, Fangheng Hu, Courtney Chambers, Annie Nguyen, Andrea Hernandez, Zeshi Wang, Peter D Rios, Sofia Ghani, Ira Joshi, Douglas Isa, Ningbo Zheng, Weiyi Peng, Oleg A Igoshin, Jose Oberholzer, H Courtney Hodges, Nathan Reticker-Flynn, Omid Veiseh

Immunotherapy biomarkers

Original research: Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy (23 April, 2025)
Nicole J Toney, Megan T Lynch, Filipa Lynce, Candace Mainor, Claudine Isaacs, Jeffrey Schlom, Renee N Donahue
Original research: Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial (15 April, 2025)
Matthew S Block, Garth D Nelson, Jun Chen, Stephen Johnson, Lu Yang, Thomas James Flotte, Eric P Grewal, Robert R McWilliams, Lisa A Kottschade, Evidio Domingo-Musibay, Svetomir N Markovic, Anastasios Dimou, Heather N Montane, Mara A Piltin, Daniel L Price, Samir S Khariwala, Jane Yuet Ching Hui, Courtney L Erskine, Carrie A Strand, David Zahrieh, Haidong Dong, Tina J Hieken
Original research: Siglec-15 antibody–GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophages (10 April, 2025)
Zemeng Ma, Xiaoyao Hao, Shuang Qu, Quanli Zhang, Jiajing Luo, Hongyan Li, Jinyu Liu, Wenwen Dai, Jun Li, Shouyong Gu, Dihan Zhu, Mingjiu Chen, Ke Zen

Letter

Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer (30 April, 2025)
Bi-Cheng Wang
Comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer” (15 April, 2025)
Shuai An, Fang-Tong Liu, Chenglong Wang
Comment on “Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)” (1 April, 2025)
Xin Rui, Tingting Gu, Jiaquan Zhou

Oncolytic and local immunotherapy

Original research: Discovery and validation of frameshift-derived neopeptides in Lynch syndrome: paving the way for novel cancer prevention strategies (20 April, 2025)
Cristina Bayó, Giancarlo Castellano, Fátima Marín, Joaquín Castillo-Iturra, Teresa Ocaña, Hardeep Kumari, Maria Pellisé, Leticia Moreira, Liseth Rivero, Maria Daca-Alvarez, Oswaldo Ortiz, Sabela Carballal, Rebeca Moreira, Julia Canet-Hermida, Marta Pineda, Capella Gabriel, Georgina Flórez-Grau, Manel Juan, Daniel Benitez-Ribas, Francesc Balaguer
Original research: β-blocker suppresses both tumoral sympathetic neurons and perivascular macrophages during oncolytic herpes virotherapy (5 April, 2025)
Konstantina Kyritsi, Rafal Pacholczyk, Eugene Douglass, Miao Yu, Hui Fang, Gang Zhou, Balveen Kaur, Qin Wang, David H Munn, Bangxing Hong
Original research: Conformation-sensitive targeting of CD18 depletes M2-like tumor-associated macrophages resulting in inhibition of solid tumor progression (5 April, 2025)
Ik-Hwan Han, Ilseob Choi, Hongseo Choi, Soyoung Kim, Chanmi Jeong, Juwon Yang, Yingying Cao, Jeongyoon Choi, Heekyung Lee, Jin Sun Shin, Hye Duck Yeom, Eun-Ji Lee, Nari Cha, Hyemin Go, Se Eun Lim, Songah Chae, Won-Jun Lee, Minjin Kwon, Hongsung Kim, Hyojung Choi, Sehyun Pak, Namgyeong Park, Eunbin Ko, Deok-Sang Hwang, Junho H Lee, Hwan-Suck Chung, Seong Ho Kang, Hyunsu Bae
Original research: Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors (1 April, 2025)
Yenan Zhang, Bohao He, Peng Zou, Mengdi Wu, Min Wei, Chuning Xu, Jie Dong, Jiwu Wei

Position article and guidelines

Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors (8 April, 2025)
Eileen L Chang, Renee Liu, Kiandokht Keyhanian, Katie Huynh, Meghan Berkenstock, M Tariq Bhatti, John J Chen, James Chodosh, Fiona Costello, Lauren A Dalvin, Lindsey B DeLott, Marc Dinkin, Robert A Egan, Clare L Fraser, Suzanne K Freitag, Sapna Gangaputra, Lynn K Gordon, Amanda C Guidon, Douglas B Johnson, Ninani Kombo, Michal Kramer, Andrew G Lee, Michael Levy, Anne-Marie Lobo-Chan, Dimosthenis Mantopoulos, George Papaliodis, Misha Pless, Julia Pimkina, Krista M Rubin, H Nida Sen, Afreen Shariff, Prem S Subramanian, Edmund Tsui, Michael K Yoon, Jon McDunn, Johnathan Rine, Kerry L Reynolds, Lucia Sobrin, Bart K Chwalisz

Review

Tailoring CAR surface density and dynamics to improve CAR-T cell therapy (29 April, 2025)
Ana Hinckley-Boned, Carmen Barbero-Jiménez, Maria Tristán-Manzano, Noelia Maldonado-Perez, Michael Hudecek, Pedro Justicia-Lirio, Francisco Martin
Expanding the CAR toolbox with high throughput screening strategies for CAR domain exploration: a comprehensive review (9 April, 2025)
Gils Roex, Khloe S Gordon, Eva Lion, Michael E Birnbaum, Sébastien Anguille

Main menu

Table of contents

April 2025 - Volume 13 - 4

Basic and translational cancer immunology

Basic tumor immunology

Case report

Clinical/translational cancer immunotherapy

Clinical cancer immunotherapy

Commentary

Hypothesis

Immune cell therapies and immune cell engineering

Immunotherapy biomarkers

Letter

Oncolytic and local immunotherapy

Position article and guidelines

Review

Correction

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

April 2025 - Volume 13 - 4

Basic and translational cancer immunology

Basic tumor immunology

Case report

Clinical/translational cancer immunotherapy

Clinical cancer immunotherapy

Commentary

Hypothesis

Immune cell therapies and immune cell engineering

Immunotherapy biomarkers

Letter

Oncolytic and local immunotherapy

Position article and guidelines

Review

Correction